Bobak Azamian, CEO and Chairman of Tarsus Pharmaceuticals, talks about revolutionizing eyecare treatment. He discusses unmet needs and patient focus, future indications they're pursuing, and leveraging learnings from previous programs. He also shares the challenges of going public during the pandemic. The podcast covers their recent product approval and the impact it had on the team, their approach to treating Blevveritis, preparing for commercialization, and the changes and challenges of leading a commercial stage company.
